Cargando…

Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment

Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhury, Supriyo, Roy, Akash, Mondal, Banashree, Singh, Ravi, Halder, Saptak, Chatterjee, Koustav, Baker, Mark R., Kumar, Hrishikesh, Baker, Stuart N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925208/
https://www.ncbi.nlm.nih.gov/pubmed/31862983
http://dx.doi.org/10.1038/s41598-019-55321-5
_version_ 1783481870466416640
author Choudhury, Supriyo
Roy, Akash
Mondal, Banashree
Singh, Ravi
Halder, Saptak
Chatterjee, Koustav
Baker, Mark R.
Kumar, Hrishikesh
Baker, Stuart N.
author_facet Choudhury, Supriyo
Roy, Akash
Mondal, Banashree
Singh, Ravi
Halder, Saptak
Chatterjee, Koustav
Baker, Mark R.
Kumar, Hrishikesh
Baker, Stuart N.
author_sort Choudhury, Supriyo
collection PubMed
description Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). After validation ocSSRT was measured in Parkinson’s disease patients without dyskinesia (PD), cervical dystonia (CD) and writer’s cramp. We also assessed how ocSSRT responded to L-dopa in PD patients and botulinum toxin injections in CD patients. Participants were instructed to release a button following a green LED flash on the device. On 25% of trials, a red LED flashed 5–195 ms after the green LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were significantly prolonged in patients with Parkinson’s disease and focal dystonia (one-way ANOVA p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is associated with PD and focal dystonia.
format Online
Article
Text
id pubmed-6925208
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69252082019-12-24 Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment Choudhury, Supriyo Roy, Akash Mondal, Banashree Singh, Ravi Halder, Saptak Chatterjee, Koustav Baker, Mark R. Kumar, Hrishikesh Baker, Stuart N. Sci Rep Article Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). After validation ocSSRT was measured in Parkinson’s disease patients without dyskinesia (PD), cervical dystonia (CD) and writer’s cramp. We also assessed how ocSSRT responded to L-dopa in PD patients and botulinum toxin injections in CD patients. Participants were instructed to release a button following a green LED flash on the device. On 25% of trials, a red LED flashed 5–195 ms after the green LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were significantly prolonged in patients with Parkinson’s disease and focal dystonia (one-way ANOVA p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is associated with PD and focal dystonia. Nature Publishing Group UK 2019-12-20 /pmc/articles/PMC6925208/ /pubmed/31862983 http://dx.doi.org/10.1038/s41598-019-55321-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Choudhury, Supriyo
Roy, Akash
Mondal, Banashree
Singh, Ravi
Halder, Saptak
Chatterjee, Koustav
Baker, Mark R.
Kumar, Hrishikesh
Baker, Stuart N.
Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
title Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
title_full Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
title_fullStr Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
title_full_unstemmed Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
title_short Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
title_sort slowed movement stopping in parkinson’s disease and focal dystonia is improved by standard treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925208/
https://www.ncbi.nlm.nih.gov/pubmed/31862983
http://dx.doi.org/10.1038/s41598-019-55321-5
work_keys_str_mv AT choudhurysupriyo slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT royakash slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT mondalbanashree slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT singhravi slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT haldersaptak slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT chatterjeekoustav slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT bakermarkr slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT kumarhrishikesh slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment
AT bakerstuartn slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment